The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
(86 - 88) Health / Social work 86 - Human health activities 86.9 - Other human health activities 86.9 - Other human health activities
200 jobs Number of planned job losses
Announcement Date
8 January 2014
Employment effect (start)
8 January 2014
Foreseen end date
8 February 2014
Description
The Institute of Immunology Zagreb, manufacturer of immunobiological medicines, has gone bankrupt and will dismiss 200 of its total 356 employees.
CEO Davorin Gajnik has made an appeal to the Commercial Court, which should make a decision regarding the suspension of the bankruptcy proceedings within a two month period. Gajnik states that he found a plasma manufacturer outside Croatia that could process the 30,000 litres of plasma supply owned by the Institute of Immunology.
In 2013, the Institute lost a manufacturing license for the production of medicines derived from human blood (or human plasma) and a serum of animal origin, resulting in a loss of 80% of its revenue. By finding these new manufacturers of plasma the Institute could potentially be granted a transition period in which it could move to a new location in Sveta Nedelja (not far from Zagreb) where it would be able to continue production. This option had been available previously, but the government did not approve the HRK 200 million (EUR 26.3 million) funds for the relocation operation.
The employees of the Institute have been given a notice period ending on 8 February 2014.
The Institute of Immunology is a public company owned by the Croatian Government one of the world’s biggest and oldest manufacturers of immuno-biological medicines.
Sources
8 January 2014: www.poslovni.hr
Citation
Eurofound (2014), Imunoloski zavod (The Institute of Immunology) Zagreb, Bankruptcy in Croatia, factsheet number 76413, European Restructuring Monitor. Dublin, https://dev.eurofound.europa.eu/restructuring-events/detail/76413.
This working paper offers a comprehensive methodological overview of the European Restructuring Monitor (ERM) databases. Even though the methodology has not changed over time, new categories have been added, and the way it has been used by researchers and policymakers...
This Eurofound research paper explores key trends in restructuring in recent years, highlighting the companies that announced the largest job losses and job gains in the EU. It builds on an analysis of company announcements recorded in Eurofound’s European Restructuring...
In 2023, thousands of workers in big tech lost their jobs. Meta, Amazon, Google, Apple, Microsoft and Salesforce had been considered to offer good and secure jobs up to this point. Giants of the information and communication technology (ICT) sector,...
In 2024, the automotive sector in the EU came to the fore in public and policy discussions. The focus was on the slowdown in electric vehicle (EV) sales, rising global competition, belated investments in new technologies, and the potential closure...
The more employee monitoring resembles surveillance – with its systematic, continuous and detailed tracking of employees' activities, behaviours or communications – the greater the potential for infringement of both privacy and data protection rights. Although the EU General Data Protection...
Since 2013, Eurofound's ERM database on restructuring-related legislation has been documenting regulatory developments in the Member States of the European Union and Norway which are explicitly or implicitly linked to anticipating and managing change. The most recent update to the...